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OUNSELLING WOMEN ABOUT THE RESOURCES 
that are available to them to assess their risk 
of breast cancer and providing advice on ap-
propriate screening and risk-reduction strategies can be 
challenging for clinicians. This article discusses genetic 
risk factors for breast cancer, how to take a family his-
tory, and how to counsel and organize appropriate re-
ferrals for patients who may be at an increased risk of 
breast cancer because of a mutation in the BRCA1 or 
BRCA2  gene. In addition, it provides information on 
counselling women who have been identified as having 
a mutation in BRCA1 or BRCA2.
C
Case
A 40-year-old patient informs you that her sister has 
been diagnosed with breast cancer at the age of 38. The 
patient’s mother, at age 65, is healthy and has never had 
a cancer diagnosis. The patient knows of no other family 
history of breast cancer on her mother’s side of the fam-
ily; her father’s grandmother possibly had breast can-
cer, but she died before the patient was born. The pa-
tient also mentions a paternal aunt who died of ovarian 
cancer. She is of Ashkenazi Jewish descent. The patient 
inquires whether she should be concerned about her 
sister’s breast cancer diagnosis and if she is too young to 
begin breast screening. How would you advise her?
Assessing breast cancer risk
Several models are available to help assess a woman’s 
risk of breast cancer. The Gail Model calculates a wo-
man’s breast cancer risk over the next five years, in ad-
dition to her lifetime risk (www.cancer.gov    /bcrisktool/    ). 
The model considers age, ethnicity, history of breast 
cancer in first-degree relatives, age of menarche, and 
previous history of breast biopsies and benign breast 
disease.
Clinicians should be familiar with the process of tak-
ing a detailed family history (pedigree) to assess cancer 
risk. This involves collecting information with regard to 
types of cancer, the ages at which cancer diagnoses were 
made, and the vital status of three generations of relat-
ives within a family. In addition, family ethnicities 
should be recorded. There are many resources available 
to help clinicians assess genetic family histories, includ-
ing a detailed list on the University of Kansas Medical 
Center website. 
Genetic testing  for  BRCA1  and  BRCA2 mutations 
helps physicians identify women who are at signific-
antly increased risk of developing breast and ovarian 
cancer. For  BRCA1  carriers, the estimated cumulative 
risks to age 70 years are 65% for breast cancer and 39% 
for ovarian cancer. The corresponding risks for BRCA2 
carriers are 45% for breast cancer and 11% for ovarian 
cancer.1 In comparison, the average woman in the gen-
eral population has an 11% lifetime risk of developing 
breast cancer and a 1.5% risk of developing ovarian can-
cer (Table 1). After the initial diagnosis of breast cancer 
in a BRCA1 or BRCA2 carrier, the risk of cancer in the 
opposite breast (a new primary cancer) increases by ap-
proximately 3% per year.2–4
Table 1: Lifetime breast cancer risk
Lifetime breast 
cancer risk
Median age of breast 
cancer onset (y)
General population 11% 61
BRCA1 65% 43
BRCA2 45% 41
About 1 in 200 women in North America carries a 
BRCA1 or BRCA2 mutation,5–7 but among several ethnic 
groups the prevalence is considerably higher. Notably, 
the frequency in those of Ashkenazi Jewish ancestry is 1 
in 50.7,8  Other groups with high frequencies of muta-
tions include women from Iceland9 and Poland.10 These 
high prevalence rates are explained by the presence of 
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founder   mutations.   (Founder   mutations   are   one   or 
more specific mutations in a population that have been 
inherited from a common ancestor, and that have be-
come amplified through chance effects, often aided by 
geographic isolation of the population.) 
Patients identified as being at increased risk for any 
familial cancers should be referred for genetic coun-
selling.   The  Ontario   Medical   Review  published 
guidelines for the referral of patients with a family his-
tory   of   cancer   to   cancer   genetics   clinics 
(www.oma.org/pcomm
/OMR/nov/    01genet    ics    .htm    ).11  These guidlines identify 
risk factors for inherited breast and ovarian cancer (Text-
box 1). The presence of one or more of these factors in an 
individual’s personal or family history may suggest an in-
creased risk for hereditary cancer and warrants a referral 
for genetic counselling. Information on genetic coun-
selling centres within Canada can be found at www.cagc-
accg.ca. 
Case revisited
The patient’s family history suggests a possible BRCA1 
or  BRCA2  mutation. She has a sister with premeno-
pausal   breast   cancer,   a   paternal   grandmother   with 
breast cancer who died at a young age, and a paternal 
aunt with ovarian cancer. Her Ashkenazi Jewish descent 
may also increase her risk of a mutation. Information is 
collected on 3 generations within the family and presen-
ted in a genetic pedigree (Figure 1), which proves to be 
suggestive of hereditary breast cancer. You refer your 
patient for genetic counselling and testing, and also sug-
gest that her sister with breast cancer seek genetic coun-
selling. Models are available to assess an individual’s 
risk of having a mutation in the BRCA1 or BRCA2 genes 
(www4.utsouthwestern.edu/breasthealth/cagene/). 
Your patient’s genetic counseller, using the BRCAPRO 
model, determines that she has a 30% lifetime risk of 
breast cancer and a 42% chance of having a BRCA1 or 
BRCA2 mutation. She then receives genetic testing and 
is found to have a  BRCA1  mutation. Your patient re-
turns to consult you and wants to know what she can do 
to prevent the development of breast cancer. What 
would you tell her?
Cancer prevention options
Ultimately, the value of genetic testing for BRCA1 and 
BRCA2 mutations comes from reducing the number of 
women who develop breast cancer and the number of 
women who die of the disease. Women with a BRCA1 or 
BRCA2  mutation   may   consider   several   options   for 
breast cancer prevention. The three main options are 
prophylactic mastectomy, prophylactic oophorectomy, 
and chemoprevention (tamoxifen or raloxifene). In ad-
dition, a woman may elect to undergo routine screen-
ing (secondary prevention) with the goal of detecting 
any cancers at an early, treatable stage.
Figure 1: A family history of cancer. The patient 
(arrow) is considered the proband.
Prophylactic mastectomy. The goal of prophylactic 
mastectomy is to prevent breast cancer, thereby elimin-
ating the potential for metastatic spread and death from 
the disease. The effectiveness of prophylactic mastec-
tomy in preventing breast cancer in BRCA1 and BRCA2 
mutation carriers has been established in a small pro-
spective   study   and   in   historical   cohort   studies   of 
primary and contralateral breast cancers. In the small 
prospective study of 26 women with a BRCA1 or BRCA2 
mutation, observed numbers of cancer were compared 
to expected numbers of breast cancer based on pen-
etrance estimates. Statistical analysis demonstrated that 
prophylactic mastectomy offered at least an 89% risk 
reduction of breast cancer in BRCA1 and BRCA2 carri-
ers.12 Meijers-Heijboer and colleagues observed no cases 
of breast cancer over 3 years among 76 women who un-
derwent prophylactic mastectomy.13  Rebbeck and col-
leagues observed 2 cases of breast cancer among 191 
women   after   mastectomy,   compared   to   184   cases 
among 378 women who did not choose mastectomy (p 
< 0.0001).14  Metcalfe and colleagues studied the devel-
opment of contralateral breast cancer in 491 women 
treated for hereditary breast cancer using various stand-
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ard surgical and adjuvant therapies.2  Only one con-
tralateral breast cancer was observed among 146 wo-
men who had undergone a contralateral mastectomy, 
versus 33 expected with no contralateral mastectomy (p 
<   0.0001).   These   studies   suggest   that   the  residual 
breast cancer risk after mastectomy is minimal (less 
than 5%), and much less than the risk of breast cancer 
in the general population. 
Total mastectomy is currently recommended over 
subcutaneous or nipple-sparing mastectomy; in the lat-
ter procedure, some breast tissue must remain below 
the nipple-areola complex to maintain the blood and 
nerve supply, and therefore there is the potential for 
breast   cancer   to   develop   in   this   residual   tissue. 
However, one systematic review previously reported 
that in all of the case studies in the literature reporting a 
failure of a subcutaneous mastectomy in the prevention 
of breast cancer, the majority of cancers did not occur in 
this residual tissue.15 As such, the risks and benefits of 
both surgical options should be discussed with patients. 
Although prophylactic mastectomy offers the best 
protection against developing breast cancer, it is known 
that the majority of women in Canada are unwilling to 
exercise this option.16  
Prophylactic oophorectomy. It has been shown that 
BRCA1-associated breast cancers are hormonally asso-
ciated.17 The purpose of an anti-hormonal therapy is to 
eliminate or block the effect of ovarian estrogen, and 
probably progesterone, or to prevent aromatization of 
androgen to estrogen. Anti-hormonal approaches in-
clude therapy with tamoxifen, raloxifene and other se-
lective estrogen receptor modulators (SERMs), ovarian 
ablation (oophorectomy, radiation or chemical ablation 
with gonadotropin-releasing hormone [GNRH] agon-
ists) and aromatase inhibition (with an agent such as 
anastrozole or letrozole). Of these, only tamoxifen and 
oophorectomy have been well studied in women with 
BRCA1 or BRCA2 mutations. 
The rationale for an anti-hormonal approach comes 
from   the   observation   that   oophorectomy   prevents 
breast cancer in  BRCA1  and  BRCA2  carriers. Cohort 
studies estimate the reduction in hereditary breast can-
cer risk associated with a premenopausal oophorectomy 
to be about 50%.18–20 A recent case-control study repor-
ted that this risk reduction may be greater if oophorec-
tomy is performed before age 40 and that the duration 
of protection is approximately 15 years.21 Short-term use 
of estrogen for menopausal symptom relief in young 
women after oophorectomy might abrogate some of the 
breast cancer protection associated with oophorectomy 
but may be important to a woman’s quality of life. In 
one study the effectiveness of prophylactic oophorec-
tomy was not reduced by the addition of hormone re-
placement therapy.20 Women who elect for prophylactic 
mastectomy should receive routine screening for osteo-
porosis associated with low estrogen. 
There are no comparable data on the degree of pro-
tection against breast cancer offered by other forms of 
ovarian ablation such as radiation or GNRH agonists. 
GNRH agonists are a reversible form of ovarian sup-
pression and thus may be preferred by a woman who 
wishes to preserve her fertility, but the use of these 
drugs in BRCA carriers is not widespread and their ef-
fectiveness in reducing breast cancer risk is unknown. 
There remains the concern that these non-surgical ap-
proaches to ovarian ablation do not address the risk for 
ovarian or fallopian tube cancers, which are also elev-
ated in BRCA1 and BRCA2 carriers. 
Selective estrogen receptor modulators. Tamox-
ifen is a selective estrogen receptor modulator (SERM) 
that competes with estrogen for binding to the estrogen 
receptor. In humans, tamoxifen acts as an estrogen ant-
agonist in breast tissue, inhibiting the growth of estro-
gen-dependent   breast   tumours.22  On   theoretical 
grounds, tamoxifen should not reduce the incidence of 
estrogen-receptor  (ER) negative breast  cancers, and 
most breast  cancers that occur  in  BRCA1  (but  not 
BRCA2) carriers are ER negative. An attempt to under-
stand the preventative role of tamoxifen was made in 
the National Surgical Adjuvant Breast and Bowel Pro-
ject — P1 trial.23 In this study, the authors compared the 
incidence of breast cancer among women who took 
tamoxifen with the incidence among those who took a 
placebo. In the cohort of 288 women who developed 
breast cancer during the study, 8 women were found to 
have a BRCA1 mutation and 11 were found to have a 
BRCA2 mutation. When cancer incidence was examined 
in this group of women with BRCA1 and BRCA2 muta-
tions, it was concluded that tamoxifen was protective 
against breast cancer in women with a BRCA2 muta-
tion, but not in those with a BRCA1 mutation. No pro-
tective effect was seen with tamoxifen for BRCA1 carri-
ers, but the number of cases is too small for the study to 
be definitive. In a large case-control study, tamoxifen 
was  found  to   reduce  the  incidence  of  contralateral 
breast cancer in affected BRCA1 and BRCA2 carriers by 
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about one-half (odds ratio = 0.5; 95% confidence inter-
val 0.30–0.85).24 If we assume that contralateral can-
cers in carriers are representative of all new primary 
breast cancers, the results of this study might be extra-
polated to the prevention of first primary breast can-
cers. But this conclusion would be invalid if the 2 
primary cancers were not independent — for example, if 
tamoxifen were given only to ER positive patients, and 
if the ER status of bilateral cancers were highly correl-
ated. In a recent study by Weitzel and colleagues, the 
majority of contralateral breast cancers after ER-posit-
ive breast cancer were in fact, estrogen-receptor negat-
ive,  suggesting  that tamoxifen prevents ER-negative 
contralateral breast cancers.25 
There are risks associated with taking tamoxifen: for 
every 10,000 women who take tamoxifen there are 15 
endometrial cancers, 2 uterine sarcomas, 4 cerebrovas-
cular events, and 5 pulmonary emboli per year above 
that expected in those not on tamoxifen.26 
Screening. The goal of screening is to identify breast 
cancer at a stage when surgical cure is likely. For women 
in the general population, this outcome would pertain to 
small (< 1 cm) node-negative tumours with no evidence 
of distant spread. However, BRCA1-associated breast tu-
mours are typically high grade and are estrogen-receptor 
negative,2 which may impart higher risk even when they 
are detected early. Although several small studies have 
been done of breast-cancer-specific survival in women 
with a BRCA1 or BRCA2 mutation,27 there is little con-
sensus on survival outcomes in this group of women. In 
one study involving BRCA1 carriers, little correlation was 
found between tumour size and lymph-node positivity, as 
would be expected with sporadic breast cancer. About 
one-third of BRCA1 carriers had lymph node metastases 
detected at diagnosis, regardless of tumour size,28 making 
it difficult to predict the benefit of screening using surviv-
al data generated from a comparison group of non-carri-
ers. 
A number of advisory groups in the United States and 
Europe have published recommendations for surveil-
lance for women at hereditary risk for breast cancer and 
ovarian cancer.29–31 In general, these guidelines called for 
annual mammography beginning around age 25, as well 
as monthly breast self-examinations (BSE) and clinical 
breast examination (CBE) once to twice a year. 
Certain   histological   features   of  BRCA1-associated 
breast cancer (e.g., the appearance of pushing margins) 
and high breast density (characteristic of young women) 
in women with a  BRCA1  or  BRCA2  mutation32  may 
make  BRCA-associated   tumours   difficult   to   detect 
mammographically. Studies conducted in the US and in 
the United Kingdom of women under 50 with a family 
history of breast cancer reported mammography sensit-
ivities of 63%–70%33 and 44%,34 respectively. Goffin and 
colleagues35 found that only 2 of 8 breast cancers (25%) 
in BRCA1 carriers were detectable by mammogram at 
diagnosis, versus 27 of 35 (77%) among non-carrier con-
trols (p = 0.01). In a large cohort at a single centre (n = 
251), of 12 breast tumours diagnosed in BRCA mutation 
carriers, fewer than half were detected by mammogram.
36 Breast magnetic resonance imaging (MRI) offers the 
promise of a greatly improved sensitivity of detection of 
breast cancers in those at high risk. Early studies repor-
ted sensitivities in the range of 100% for invasive breast 
cancer, but later studies that included ductal carcinoma 
in situ (DCIS) reported lower sensitivities.36–43  In the 
largest series reported to date, the sensitivity of MRI 
was 83% for invasive disease but was only 71% overall.44 
However, the benefit attributable to finding cases of 
DCIS (versus early invasive cancers) has not been estab-
lished. In a study with longitudinal follow-up, MRI de-
tected 9 breast tumours that were missed by the other 
screening modalities.45 Of note, only 2 of the 22 women 
with breast cancer (9%) detected in this Canadian trial 
had lymph node metastases. Thus, we feel that MRI has 
a role in screening BRCA mutations carriers. It is not 
clear if the addition of mammography to MRI improves 
the sensitivity of screening. 
Case revisited
Your patient is  BRCA1  positive, and women with a 
BRCA1  or  BRCA2  mutation   represent   the   group   at 
highest risk for breast cancer. She should be made aware 
of her options to reduce her cancer risk. Prophylactic 
mastectomy has the greatest likelihood of preventing 
cancer but is not acceptable to many women. The risk re-
ductions resulting from tamoxifen and prophylactic oo-
phorectomy are lower (approximately 50% risk reduction 
for each) and are associated with the side effects of hor-
mone withdrawal and infertility. For these reasons, for 
many women screening is the preferred option. 
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